MX2024013187A - Anticuerpos biespecíficos y métodos de tratamiento de las enfermedades oculares - Google Patents

Anticuerpos biespecíficos y métodos de tratamiento de las enfermedades oculares

Info

Publication number
MX2024013187A
MX2024013187A MX2024013187A MX2024013187A MX2024013187A MX 2024013187 A MX2024013187 A MX 2024013187A MX 2024013187 A MX2024013187 A MX 2024013187A MX 2024013187 A MX2024013187 A MX 2024013187A MX 2024013187 A MX2024013187 A MX 2024013187A
Authority
MX
Mexico
Prior art keywords
amd
bispecific antibodies
treatment methods
eye diseases
neovascular
Prior art date
Application number
MX2024013187A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Peterson
Original Assignee
Broadwing Bio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broadwing Bio Llc filed Critical Broadwing Bio Llc
Publication of MX2024013187A publication Critical patent/MX2024013187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024013187A 2022-04-29 2024-10-25 Anticuerpos biespecíficos y métodos de tratamiento de las enfermedades oculares MX2024013187A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263336766P 2022-04-29 2022-04-29
PCT/US2023/020365 WO2023212298A1 (en) 2022-04-29 2023-04-28 Bispecific antibodies and methods of treating ocular disease

Publications (1)

Publication Number Publication Date
MX2024013187A true MX2024013187A (es) 2025-02-10

Family

ID=86688568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013187A MX2024013187A (es) 2022-04-29 2024-10-25 Anticuerpos biespecíficos y métodos de tratamiento de las enfermedades oculares

Country Status (10)

Country Link
US (1) US20250346653A1 (enExample)
EP (1) EP4514845A1 (enExample)
JP (1) JP2025514437A (enExample)
KR (1) KR20250018169A (enExample)
CN (1) CN119487063A (enExample)
AU (1) AU2023260823A1 (enExample)
CL (1) CL2024003285A1 (enExample)
IL (1) IL316615A (enExample)
MX (1) MX2024013187A (enExample)
WO (1) WO2023212298A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024227154A1 (en) * 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12378314B1 (en) * 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
EP1002078A1 (en) 1997-07-31 2000-05-24 Chiron Corporation Method enabling readministration of aav vector via immunosuppresion of host
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
US6399385B1 (en) 1999-09-29 2002-06-04 The Trustees Of The University Of Pennsylvania Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
PL2357189T3 (pl) 2003-06-19 2017-08-31 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
KR101572700B1 (ko) 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
JP6138018B2 (ja) 2013-10-03 2017-05-31 三菱電機株式会社 赤外線固体撮像素子
EA037120B1 (ru) 2015-02-02 2021-02-09 МЕИРЭДжТиЭкс ЮКей II ЛИМИТЕД Регулирование экспрессии генов посредством аптамер-опосредованного модулирования альтернативного сплайсинга
US20160346359A1 (en) 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
CA3019126A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
US20210371877A1 (en) 2017-12-18 2021-12-02 Spark Therapeutics, Inc. Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
EP3784697A4 (en) 2018-04-27 2022-07-06 Spark Therapeutics, Inc. GMO AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS CONTAINING THE GMO CAPSIDS, AND METHODS FOR THEIR MANUFACTURE AND USE
JP2021522813A (ja) 2018-05-07 2021-09-02 スパーク セラピューティクス インコーポレイテッドＳｐａｒｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． プラスミドを用いないａａｖベクター産生細胞株
CN112470003A (zh) * 2018-05-10 2021-03-09 曼彻斯特大学 评估黄斑变性的方法
BR112021009452A2 (pt) 2018-11-16 2021-08-17 Spark Therapeutics, Inc. ensaio in vitro para detectar intensificadores e inibidores de transdução de vetor de vírus adeno-associados (aav) e/ou detectar ou quantificar anticorpos de ligação a anti-aav

Also Published As

Publication number Publication date
EP4514845A1 (en) 2025-03-05
IL316615A (en) 2024-12-01
US20250346653A1 (en) 2025-11-13
WO2023212298A1 (en) 2023-11-02
JP2025514437A (ja) 2025-05-02
CN119487063A (zh) 2025-02-18
CL2024003285A1 (es) 2025-04-04
KR20250018169A (ko) 2025-02-04
AU2023260823A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
CL2024003285A1 (es) Anticuerpos bispecíficos y métodos de tratamiento de enfermedades oculares
AR036401A1 (es) Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
SA520420801B1 (ar) أil جسام مضادة لـ -11
CO2020000772A2 (es) Conjugado de anticuerpo monoclonal contra bcma -fármaco incorporación por referencia de material presentado electrónicamente
MX2021013197A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
MX2023013245A (es) Rescorcinoles, metodos para su fabricacion, y usos de los mismos.
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
MX2021005518A (es) Modelos animales, métodos de detección y métodos de tratamiento para enfermedades o trastornos intraoculares.
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
MA41596B1 (fr) Anticorps anti-tau et leurs utilisations
MX2021011242A (es) Conjugados de vesícula extracelular y usos de estos.
CL2023000853A1 (es) Compuestos y composiciones como moduladores de señalización tlr
EA202190162A2 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
JOP20230250A1 (ar) تركيبات وطرق لتثبيط إنزيم كيتوهيكسوكيناز (khk)
MY185811A (en) Novel anti-human tie-2 antibody
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
MX2024007220A (es) Psicoplastogenos de pirrolidina fusionada y sus usos.
DOP2024000117A (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
WO2019180688A3 (en) Compositions and methods for treating diarrheal diseases
MA40305B2 (fr) Composition nématicide et son utilisation